

Cost Review Study Report- Jardiance

PDAB Meeting

April 13, 2026

PDAB Staff



Actions Taken As Part of the Cost Review Study Process

- **Board Deliberated on July 28, 2025 and made preliminary determinations**
- **Board Staff prepared a draft cost review study report containing**
 - Summary of Information Considered by the Board
 - Summary of Deliberations
 - Circumstances and Indicia Reflecting the Affordability Challenge
 - Preliminary Determination
- **Draft Posted for Public Comment: March 16, 2026**
 - Comments Due: March 30, 2026
- **Staff Published an Revised Draft on April 6, 2026**



Finalizing the Cost Review Study Report

- G. Final Determination Concerning Affordability Challenge and Final Cost Review Study Report.
 - (1) The Board may vote to finalize the preliminary determination and approve the draft cost review report as final.
 - (2) The Board's determination of whether a prescription drug has or will lead to an affordability challenge is not final until the final cost review report is adopted by the Board.
 - (3) The Board shall create and adopt a final report of the cost review study that, to the extent permitted by Health-General Article, §§21-2C-03 and 21-2C-10, Annotated Code of Maryland, summarizes the information considered by the Board in conducting the cost review study, the Board's deliberations, and the Board's determination.



Board Cost Review Tasks for this Meeting

- **Review:** Public comments on draft report
- **Discuss:** Revised draft report
- **Move:** Adopt Final determination of affordability challenge
- **Deliberate:** Final determination of affordability challenge
- **Vote:** Adopt resolution with final affordability challenge determination
 - Staff will update the report to reflect these deliberations
- **Vote:** Adopt the final cost review study report



Summary of Comments Received on Draft Report-Jardiance

- **PDAB staff received a total of 2 comments on the Jardiance Draft Cost Review Report for the comment period ending on March 30, 2026.**
 - Maryland Health Benefit Exchange (MHBE)
 - PhRMA
- **Feedback Themes Included:**
 - Concerns about the accuracy and validity of the data used in the cost reviews
 - “Affordability challenge” lacks clear definition
 - Call for transparency in data weighting and analysis methodology from closed session
 - Concerns about definition of “therapeutic alternatives”, ensure alignment with clinical evidence
 - Call for transparency on how public comment is incorporated in decision-making process
 - Consideration of clinical value and cost offsets in analysis
 - Specifically the prevention of expensive medical outcomes
 - The fiscal impact of Jardiance on Maryland’s individual health insurance market and the State Reinsurance Program



Support of Jardiance Findings in the Cost Review Study Report

- **One commenter noted the importance of findings of the Cost Review Study Report for Jardiance because of the impact that Jardiance has on the health plans**
 - **The commenter supported the Board's findings, with spending on less than 2000 patients taking Jardiance representing over 1.5% of the total prescription drug spend brand name prescription drug claims costs in the individual market**

Reponse: The PDAB thanks the commenters for their input

Proposed Updates: No changes



Need for Certain Definitions

- **One commenter noted concerns with the standards for making the determination if a drug has led or will lead to affordability challenges for the state health care system or high out-of-pocket costs for patients. This includes the circumstances identified by the Board under which the cost of a prescription drug product has led or will lead to affordability challenges for the State health care system and patients without explicitly defining affordability.**

Reponse: The PDAB thanks the commenters for their input. The Board's current process aligns with the statutory requirements. The Board may update the process for future rounds of Cost Review Studies to define and standardize the determination that drugs have led or will lead to an affordability challenge.

Proposed Updates: No changes.



Need for Additional Transparency in the Process

- **One commenter noted concerns with transparency in the Cost Review Study Process, including substantial deliberations occurring in Closed Session to allow the Board to discuss confidential, trade-secret, and proprietary information.**

Reponse: The PDAB thanks the commenters for their input. The Board's current process aligns with the statutory requirements. However, the Board supports a clear and transparent process. The Board complies with its obligation to consider confidential, trade-secret, and proprietary information in closed session.

Proposed Updates: Board has revised the cost review study report to include closed session deliberations but has protected the confidential data and information through redaction.



Clear Process for Accounting for Comments and Stakeholder Input

- **One commenters noted concerns with how comments are being captured and considered as part of the Cost Review Study Process.**

Reponse: The PDAB thanks the commenters for their input. The Board receives and considers all comments and public input collected in the Cost Review Study Process. The Board will continue to look for opportunities to clearly demonstrate how comments are considered.

Proposed Updates: No changes



Incorporated Changes

- Staff has updated the draft report to include:
 - More details about the deliberations and the analyses that went into the determinations made in closed session;
 - Additional comments on the study report



Next Steps

- **Move:** To adopt final affordability challenge determination
- **Deliberate:** On final affordability challenge determination
- Board staff prepares final resolution and a final report
- **Vote:** Adopt resolution with final affordability challenge determination
 - Staff will update the report to reflect these deliberations
- **Vote:** Adopt the final cost review study report





MARYLAND
Prescription Drug Affordability Board

support.pdab@maryland.gov
pdab.maryland.gov